Drug treatment of endocrine disorders

Chapter 16 Drug treatment of endocrine disorders





INTRODUCTION


Endocrine disorders due to under- or overproduction of hormones are a major cause of morbidity and mortality. Certain endocrine disorders are a particular feature of life in the twenty-first century. The increasing levels of obesity on a worldwide scale, especially in the prosperous economies of the world, are associated with very high levels of diabetes. People in the UK with diabetes have broken the 2 million mark. Although great progress has been made in the treatment of both types of diabetes (improved oral hypoglycaemic agents, parenteral and inhaled insulin, diagnostic procedures and management), major concerns remain. Diabetes may be underdiagnosed by as much as 25% (Health and Social Care Information Centre 2005). Underdiagnosis, together with poor management by patients, greatly increases the risk of serious complications developing (cardiac, renal, ophthalmic, neuropathy). There is a major need for public education on diet and related matters to ensure that the risks of being unhealthy are well known and understood. Specialist health professionals can do much both in the field of prevention and the improvement of outcomes for patients.


Excellent treatments are available for many con-ditions in which an endocrine deficiency has been diagnosed. Such treatments greatly improve the quality of life for many patients. Treatment with drugs that block the production of hormones are of great importance in the treatment of malignant disease. It is difficult to overestimate the value of corticosteroids in a wide range of conditions – from oral and parenteral use in life-threatening diseases to topical application for serious and debilitating skin conditions. Many older people have benefited from drugs used in the treatment of disorders of bone metabolism.


Nurses in all branches of the profession have an increasing role in the management of endocrine disorders, especially diabetes. All the indications are that this role will expand as the future burden of diabetes and even more frighteningly its complications increase (Diabetic Medicine 2002).



HORMONAL REGULATION


Although each ductless gland (Fig. 16.1) produces a hormone with specific functions, there is an integrated relationship between the activities of the glands. If these relationships are disturbed by a disease process, the consequences can be far reaching.



The hypothalamus and the pituitary gland together form the central control unit for the production and secretion of many hormones. The hypothalamus produces ‘releasing’ and ‘inhibiting’ hormones that influence the anterior lobe of the pituitary gland to release corresponding hormones, the trophic hormones, some of which affect target cells in the body directly while others do so through the intermediary of a second endocrine organ such as the thyroid, the adrenal cortex and the gonads. The second endocrine organ, in turn, produces a third specific hormone such as levothyroxine sodium (thyroxine sodium), corticosteroids or sex hormones, which influences various other body functions.


Chemoreceptors in the hypothalamus register the blood hormone level and react accordingly by either increasing or decreasing hormone production. If the blood hormone level is low, more hormone is secreted; if the blood hormone level is high, hormone production is reduced (negative feedback; see Fig. 16.2). Not all hormonal activities, however, follow this mechanism.




HYPOTHALAMUS AND PITUITARY GLAND


The hypothalamus forms the base of the brain (diencephalon). It is responsible for the coordination of nervous and endocrine systems and therefore many basic life functions such as cardiovascular, respiratory and alimentary functions, sexual behaviour and reproduction. It is connected to the pituitary gland, a small endocrine gland of great importance, by the hypophyseal stalk or infundibulum. The pituitary gland lies almost completely surrounded by bone in the base of the skull. It consists of three parts: the anterior lobe (adenohypophysis), the median eminence and the posterior lobe (neurohypophysis).


The anterior pituitary (see Fig. 16.3) synthesises and releases seven known trophic hormones. These are somatotrophin, which is involved in prepubertal body growth; prolactin, which stimulates the growth and secretory activity of the female breasts during pregnancy; melanocyte-stimulating hormone, which causes an increase in cutaneous pigmentation; adrenocorticotrophic hormone (ACTH), which governs the secretions of some of the hormones by the adrenal cortex; thyrotrophin (thyroid-stimulating hormone, TSH), which stimulates thyroid activity; follicle-stimulating hormone or human menopausal gonadotrophin, which stimulates growth of ovarian follicles and secretion of oestrogen in the female and spermatogenesis in the male; and luteinising hormone, which stimulates the production of progesterone in the corpus luteum of the follicle (female) and activates androgen secretion by the Leydig cells of the testis (male).



The posterior pituitary (see Fig. 16.4) hormones vasopressin (antidiuretic hormone, ADH) and oxytocin are produced in the hypothalamus and secreted (neurosecretion) directly into the bloodstream of the infundibulum and posterior lobe of the pituitary gland, from where they can be released into the body.



Vasopressin controls the reabsorption of water by the kidney tubules. In large doses, it causes vaso-constriction of the smooth muscles with a concomitant rise in blood pressure. It also causes muscle contraction in the gastrointestinal tract and uterus.


Oxytocin causes the contraction of the uterine muscle towards the end of pregnancy and at partu-rition, and contraction of the mammary smooth muscle, which stimulates the release of milk into the ducts. The secretion of oxytocin from the pituitary gland is stimulated by the baby sucking at the mother’s breast.



COMMON DISORDERS OF THE PITUITARY GLAND





MAIN DRUG GROUPS



HYPOTHALAMIC HORMONES AND ANTERIOR PITUITARY HORMONES





SOMATROPIN (SYNTHETIC HUMAN GROWTH HORMONE)


Somatropin, a biosynthetic human growth hormone, has replaced growth hormone of human origin, which has been implicated as a cause of Creutzfeldt–Jakob disease. The infectious agent involved in Creutzfeldt–Jakob disease is a protein known as a prion.




POSTERIOR PITUITARY HORMONES



VASOPRESSIN (ANTIDIURETIC HORMONE)


The use of vasopressin, a peptide with antidiuretic and vasoconstrictor properties, has declined since the development of more selective semisynthetic analogues desmopressin and terlipressin. Desmopressin has no vasoconstrictor effect, but it has an increased antidiuretic activity and a longer duration of action than vasopressin (synthetic porcine vasopressin); terlipressin is used for its vasoconstrictor effects.






DOPAMINE RECEPTOR STIMULANTS (DOPAMINERGIC DRUGS)


Bromocriptine is chemically related to ergotamine and is a stimulant for dopamine receptors in the brain. It also inhibits the release of prolactin and growth hormone from the pituitary.









COMMON DISORDERS OF THE THYROID GLAND




HYPERTHYROIDISM


Hyperthyroidism (thyrotoxicosis) results from exposure of the body tissues to excess circulating levels of free levothyroxine and/or free liothyronine. It is a fairly common disorder that affects women more than men.


It is very important to establish the cause of hyperthyroidism to be able to provide adequate treatment. The most common conditions are:





Hyperthyroidism causes an increase in the basal metabolic rate and affects almost every system in the body. It presents with a wide variety of symptoms and severity. Symptoms include:










Thyrotoxic crisis (‘thyroid storm’) is a life-threatening increase in the severity of the clinical features of thyrotoxicosis and requires immediate treatment. It is very unusual but may occur after subtotal thyroidectomy, may occur within a few days after administration of radioactive sodium iodide-131, or may be precipitated by infection in a patient with hyperthyroidism that is inadequately controlled by antithyroid drugs.


Treatment includes intravenous fluids, hydro-cortisone intravenously, propranolol (or nadolol) to control cardiac symptoms, oral iodine solution and an antithyroid drug such as carbimazole or propylthiouracil by nasogastric tube required.





MAIN DRUG GROUPS



THYROID HORMONES


Levothyroxine (thyroxine) and liothyronine are the naturally occurring thyroid hormones. Liothyronine, with a half-life of 1–2 days, has a much faster onset of action than levothyroxine, with a half-life of 7 days. Levothyroxine reaches its maximum effect after about 10 days. The difference in the onset of action is important for the therapeutic use of thyroid hormones.









ANTITHYROID DRUGS



CARBIMAZOLE AND PROPYLTHIOURACIL


Carbimazole and propylthiouracil prevent the conversion of iodide to iodine, the incorporation of iodine into the prehormonal stages and therefore the production of thyroid hormones.




Stay updated, free articles. Join our Telegram channel

May 13, 2017 | Posted by in NURSING | Comments Off on Drug treatment of endocrine disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access